James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA.
Department of Public Health, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Oncologist. 2020 Jan;25(1):e94-e108. doi: 10.1634/theoncologist.2019-0406. Epub 2019 Sep 30.
Polypharmacy (PP) and potentially inappropriate medications (PIM) are highly prevalent in older adults with cancer. This study systematically reviews the associations of PP and/or PIM with outcomes and, through a meta-analysis, obtains estimates of postoperative outcomes associated with PP in this population.
We searched PubMed, Embase, Web of Science, and Cochrane Register of Clinical Trials using standardized terms for concepts of PP, PIM, and cancer. Eligible studies included cohort studies, cross-sectional studies, meta-analyses, and clinical trials which examined outcomes associated with PP and/or PIM and included older adults with cancer. A random effects model included studies in which definitions of PP were consistent to examine the association of PP with postoperative complications.
Forty-seven articles met the inclusion criteria. PP was defined as five or more medications in 57% of the studies. Commonly examined outcomes included chemotherapy toxicities, postoperative complications, functional decline, hospitalization, and overall survival. PP was associated with chemotherapy toxicities (4/9 studies), falls (3/3 studies), functional decline (3/3 studies), and overall survival (2/11 studies). A meta-analysis of four studies indicated an association between PP (≥5 medications) and postoperative complications (overall odds ratio, 1.3; 95% confidence interval [1.3-2.8]). PIM was associated with adverse outcomes in 3 of 11 studies.
PP is associated with postoperative complications, chemotherapy toxicities, and physical and functional decline. Only three studies showed an association between PIM and outcomes. However, because of inconsistent definitions, heterogeneous populations, and variable study designs, these associations should be further investigated in prospective studies.
Polypharmacy and potentially inappropriate medications (PIM) are prevalent in older adults with cancer. This systematic review summarizes the associations of polypharmacy and PIM with health outcomes in older patients with cancer. Polypharmacy and PIM have been associated with postoperative complications, frailty, falls, medication nonadherence, chemotherapy toxicity, and mortality. These findings emphasize the prognostic importance of careful medication review and identification of PIM by oncology teams. They also underscore the need to develop and test interventions to address polypharmacy and PIM in older patients with cancer, with the goal of improving outcomes in these patients.
癌症老年患者普遍存在多重用药(PP)和潜在不适当药物(PIM)的情况。本研究系统地综述了 PP 和/或 PIM 与结局的相关性,并通过荟萃分析获得了该人群中与 PP 相关的术后结局的估计值。
我们使用标准化术语搜索了 PubMed、Embase、Web of Science 和 Cochrane 临床试验注册中心,这些术语涉及 PP、PIM 和癌症的概念。纳入的研究包括队列研究、横断面研究、荟萃分析和临床试验,这些研究检查了与 PP 和/或 PIM 相关的结局,并纳入了患有癌症的老年患者。采用随机效应模型纳入了定义一致的 PP 的研究,以检查 PP 与术后并发症的关系。
有 47 篇文章符合纳入标准。57%的研究中 PP 的定义为使用五种或以上药物。常被检查的结局包括化疗毒性、术后并发症、功能下降、住院和总生存。PP 与化疗毒性(4/9 项研究)、跌倒(3/3 项研究)、功能下降(3/3 项研究)和总生存(2/11 项研究)相关。四项研究的荟萃分析表明,PP(≥5 种药物)与术后并发症(总优势比,1.3;95%置信区间[1.3-2.8])之间存在关联。11 项研究中有 3 项研究表明 PIM 与不良结局相关。
PP 与术后并发症、化疗毒性以及身体和功能下降有关。仅有三项研究显示 PIM 与结局之间存在关联。然而,由于定义不一致、人群异质性和研究设计不同,这些关联需要在前瞻性研究中进一步探讨。
癌症老年患者中普遍存在多重用药和潜在不适当药物(PIM)的情况。本系统综述总结了 PP 和 PIM 与老年癌症患者健康结局的相关性。PP 和 PIM 与术后并发症、虚弱、跌倒、药物不依从、化疗毒性和死亡率有关。这些发现强调了由肿瘤团队进行仔细的药物审查和识别 PIM 的重要性,以预测预后。它们还强调了需要开发和测试干预措施,以解决老年癌症患者的多重用药和 PIM 问题,从而改善这些患者的结局。